Cargando…
Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
A 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient's visual acuity (VA) improved from 20/120 to 20/40 with a dry macula on spectral-domain optical-coherence tomograp...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303153/ https://www.ncbi.nlm.nih.gov/pubmed/35874928 http://dx.doi.org/10.1155/2022/3442306 |
_version_ | 1784751792378085376 |
---|---|
author | Chakraborty, Somnath Sheth, Jay Umed |
author_facet | Chakraborty, Somnath Sheth, Jay Umed |
author_sort | Chakraborty, Somnath |
collection | PubMed |
description | A 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient's visual acuity (VA) improved from 20/120 to 20/40 with a dry macula on spectral-domain optical-coherence tomography (SD-OCT). After observation, the VA improved further to 20/32 with absence of any fluid on the SD-OCT at three months. No ocular or systemic adverse events were noted. In conclusion, intravitreal brolucizumab (IB) is an efficacious and safe therapeutic option for the management of CNV secondary to AS. Further prospective studies with a larger sample size, varied therapeutic regimens, and longer follow-up period are needed to corroborate our findings. |
format | Online Article Text |
id | pubmed-9303153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-93031532022-07-22 Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks Chakraborty, Somnath Sheth, Jay Umed Case Rep Ophthalmol Med Case Report A 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient's visual acuity (VA) improved from 20/120 to 20/40 with a dry macula on spectral-domain optical-coherence tomography (SD-OCT). After observation, the VA improved further to 20/32 with absence of any fluid on the SD-OCT at three months. No ocular or systemic adverse events were noted. In conclusion, intravitreal brolucizumab (IB) is an efficacious and safe therapeutic option for the management of CNV secondary to AS. Further prospective studies with a larger sample size, varied therapeutic regimens, and longer follow-up period are needed to corroborate our findings. Hindawi 2022-07-14 /pmc/articles/PMC9303153/ /pubmed/35874928 http://dx.doi.org/10.1155/2022/3442306 Text en Copyright © 2022 Somnath Chakraborty and Jay Umed Sheth. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Chakraborty, Somnath Sheth, Jay Umed Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
title | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
title_full | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
title_fullStr | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
title_full_unstemmed | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
title_short | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
title_sort | intravitreal brolucizumab for choroidal neovascularization associated to angioid streaks |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303153/ https://www.ncbi.nlm.nih.gov/pubmed/35874928 http://dx.doi.org/10.1155/2022/3442306 |
work_keys_str_mv | AT chakrabortysomnath intravitrealbrolucizumabforchoroidalneovascularizationassociatedtoangioidstreaks AT shethjayumed intravitrealbrolucizumabforchoroidalneovascularizationassociatedtoangioidstreaks |